ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Open access · hybridAbstract read
In one paragraph
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants.Nature communications · 2025Trial
- Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.Bone marrow transplantation · 2021Trial
- NK cell immunotherapy after analytic treatment interruption is associated with HIV viral control.Molecular therapy. Advances · 2026Article
- A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host Disease.bioRxiv : the preprint server for biology · 2026Article
- Updated EBMT/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism.Bone marrow transplantation · 2026Review
- Article
- Article
- NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control.bioRxiv : the preprint server for biology · 2025Article
- Incidence and Factors Associated with Graft-Versus-Host Disease in the First Year After Allogeneic Peripheral Blood Stem Cell Transplantation.Journal of immunotherapy and precision oncology · 2025Article
- Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation.American journal of hematology · 2025Observational
- Is Contrast-Enhanced Ultrasonography a New, Reliable Tool for Early-Graft-versus-Host Disease Diagnosis?Journal of clinical medicine · 2024Review
- Associations between acute and chronic graft-versus-host disease.Blood advances · 2024Article
- Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2024Article
- Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation.Bone marrow transplantation · 2023Article
- GVHD relapse-free survival after peripheral blood hematopoietic cell transplantation for hematologic malignancies.Blood cell therapy · 2023Article
- Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy.Blood advances · 2023Article
- Acute graft-versus-host disease.Nature reviews. Disease primers · 2023Review
- Extensive acute cutaneous graft versus host disease: A rare case report of survival.Clinical case reports · 2023Article
- Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon.Frontiers in transplantation · 2023Article
- Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
71 authors at 20 institutions in 12 countries.
Annie ImUniversity of Pittsburgh/UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Armin RashidiDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Tao WangDepartment of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
Michael HemmerDepartment of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.
Margaret L MacMillanBlood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Joseph PidalaH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Madan JagasiaVanderbilt University Medical Center, Nashville, Tennessee.
Steven PavleticImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Navneet S MajhailBlood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
Daniel WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Hisham Abdel-Azim(0)Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Vaibhav AgrawalDivision of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
A Samer Al-Homsi(2)New York University Langone Medical Center, New York, New York.
Mahmoud Aljurf(3)Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Medhat Askar(4)Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, Texas.
Jeffery J Auletta(5)Blood and Marrow Transplant Program and Host Defense Program, Divisions of Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
Asad Bashey(6)Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.
Amer Beitinjaneh(7)Department of Hematology and Oncology, University of Miami, Miami, Florida.
Vijaya Raj Bhatt(8)The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
Michael ByrneVanderbilt University Medical Center, Nashville, Tennessee.
Jean-Yves CahnDepartment of Hematology, CHU Grenoble Alpes, Grenoble, France.
Mitchell Cairo(0)Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, New York.
Paul Castillo(1)UF Health Shands Children's Hospital, Gainesville, Florida.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.
Saurabh ChhabraDepartment of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.
Hannah Choe(3)James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Stefan Ciurea(4)The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew Daly(5)Tom Baker Cancer Center, Calgary, Alberta, Canada.
Miguel Angel Diaz Perez(6)Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Nosha Farhadfar(7)Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.
Shahinaz M Gadalla(8)Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland.
Robert GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
Siddhartha Ganguly(0)Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Usama Gergis(1)Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Rabi Hanna(2)Cleveland Clinic Foundation, Cleveland, Ohio.
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, Wisconsin.
Roger Herzig(4)University of Kentucky Chandler Medical Center, Louisville, Kentucky.
Gerhard C Hildebrandt(5)Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
Deepesh P Lad(6)Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Catherine Lee(7)Utah Blood and Marrow Transplant Program at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Leslie Lehmann(8)Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts.
Lazaros Lekakis(7)Department of Hematology and Oncology, University of Miami, Miami, Florida.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Mohamed A Kharfan-Dabaja(0)Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Pooja Khandelwal(1)Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; (2)Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio.
Rodrigo Martino(3)Divison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Hemant S Murthy(0)Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida.
Tracey A O'Brien(5)Blood & Marrow Transplant Program, Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia.
Richard F Olsson(6)Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; (7)Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Sagar S Patel(8)Blood and Marrow Transplant Program, University of Utah, Salt Lake City, Utah.
Miguel-Angel PeralesAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Tim Prestidge(0)Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
Muna Qayed(1)Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Rizwan Romee(2)Dana Farber Cancer Institute, Boston, Massachusetts.
Hélène Schoemans(3)Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Sachiko Seo(4)Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Melhem Solh(6)The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.
Roger Strair(7)Rutgers Cancer Institute of New Jersey, Rutgers University, Brunswick, New Jersey.
Takanori Teshima(8)Hokkaido University Hospital, Sapporo, Japan.
Alvaro Urbano-IspizuaDepartment of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS, and Institute of Research Josep Carreras, Barcelona, Spain.
Marjolein Van der Poel(0)Maastricht University Medical Center, Maastricht, the Netherlands.
Ravi Vij(1)Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri.
John L Wagner(2)Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Basem William(3)Division of Hematology, The Ohio State University, Columbus, Ohio.
Baldeep Wirk(4)Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, Pennsylvania.
Jean A Yared(5)Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Steve R SpellmanDepartment of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.
Mukta AroraDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Betty K HamiltonBlood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio. Electronic address: hamiltb2@ccf.org.
Medical College of Wisconsin · USUniversity of Minnesota · USCleveland Clinic · USDana-Farber Cancer Institute · USMayo Clinic in Florida · USMoffitt Cancer Center · USNorthside Hospital · USThomas Jefferson University · USUniversity of Miami · USVanderbilt University Medical Center · USAlbert B. Chandler Hospital · USBaylor College of Medicine · USBaylor University Medical Center · USCancer Genetics (United States) · USCentre Hospitalier Universitaire de Grenoble · FRDokkyo Medical University · JPEmory University · USFlorida College · USHokkaido University Hospital · JPHospital de Sant Pau · ES
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MGenetic Epidemiology of Telomere Maintenance and Cancer EtiologyZIACP010190 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$10.2MImmuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR)U24CA233032 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI PASQUINI, MARCELO C. · 2018 to 2019
$9.0MRandomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5MThe role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4MIdentifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6MSelection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA GenotypesR01HL129472 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2015 to 2019
$2.6MHematopoietic Stem Cell Transplantation for Young Adults with SCD - DCCU01HL128568 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI EAPEN, MARY, MENDIZABAL, ADAM M. · 2015 to 2019
$1.7MCost Effectiveness Analysis of Stem Cell Transplant in Older MDS PatientsR01HL126589 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAMSEY, SCOTT D., SABER, WAEL · 2015 to 2018
$1.7MNCI NIH HHS P01 CA111412NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA231141NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS U01 AI126612
Abstract
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus <29 years) was significantly associated with higher rates of grade 2 to 4 acute GVHD (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.11 to 2.12; P = .01). In contrast, PB compared to BM as a stem cell source was a significant risk factor for the development of chronic GVHD (HR, 1.70; 95% CI, 1.11 to 2.62; P = .01) in the RIC setting. There were no differences in relapse or overall survival between groups. Donor age and graft source are risk factors for acute and chronic GVHD, respectively, after PTCy-based haplo-HCT. Our results indicate that in RIC haplo-HCT, the risk of chronic GVHD is higher with PB stem cells, without any difference in relapse or overall survival.
Indexed as
Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultCyclophosphamideHumansRisk FactorsTransplantation ConditioningCyclophosphamide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.